TSX runs higher on rate cut expectations
SAN FRANCISCO—Becklund Irene, the Principal Accounting Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold a portion of her holdings in the company. According to a recent SEC filing, Irene sold 2,203 shares of Class A Common Stock at a price of $28.78 per share, amounting to a total transaction value of $63,402.
Following this sale, Irene holds 8,007 shares directly. The sale was conducted under a Rule 10b5-1 trading plan, which was adopted on August 7, 2024. This type of plan allows insiders of publicly traded corporations to set up a predetermined schedule for selling stocks they own, which can help avoid potential accusations of insider trading. According to InvestingPro data, HIMS currently trades at $25.99, with analyst targets ranging from $21 to $85 per share.
Hims & Hers Health, known for its telehealth services, continues to be a focal point for investors tracking developments in the healthcare technology sector.
In other recent news, Hims & Hers Health, Inc. has made notable strides in expanding its pharmaceutical offerings. The company announced it will now offer both branded and generic versions of key diabetes and weight-loss medications, including Eli Lilly (NYSE:LLY)’s Zepbound and a generic version of liraglutide. This expansion is seen as a strategic move to cater to growing consumer demand for diverse treatment options. Analysts from Truist Securities, Leerink Partners, and BofA Securities have all weighed in on these developments. Truist maintains a Hold rating with a $39 price target, noting the potential marketing benefits of these new offerings. Leerink Partners maintains a Market Perform rating with a $40 target, emphasizing the need to observe market reception, particularly for the high-cost Zepbound. Meanwhile, BofA Securities continues to rate the stock as Underperform with a $22 target, citing concerns over the low margin potential of branded drugs like Zepbound. These recent developments have sparked investor interest, reflecting optimism about Hims & Hers’ strategy to broaden its product lineup.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.